SparingVision
Translating Pioneering Science into Vision-Saving Treatments
- Website
- sparingvision.com
- Total Funding
- $71.0M
- Last Round
- $71.0M Series BSep 2022
- Rounds
- 2
About
SparingVision is a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. The company is going beyond single gene correction therapies to deliver new treatments to patients affected by blinding retinal diseases, regardless of genetic cause. Its lead pipeline targets Retinitis Pigmentosa, a group of inherited retinal diseases that is a leading cause of blindness globally, where current treatment approaches are not applicable to all patients.
Summary
SparingVision is a Biotech company. It has raised $71.0M in total across 2 rounds, most recently a $71.0M Series B round in Sep 2022. Investors include Jeito Capital, UPMC Enterprises and 4BIO Capital.
Funding History
Sep 2022
Sign up to see all 2 rounds
Series A through Series B — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Altos Labs combines academic science and industry development to create medicines that restore ce...
BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Calico researches human aging using advanced technologies and model systems, applying that knowle...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/sparingvision"><img src="https://indexed.vc/api/badge/company/sparingvision" alt="SparingVision on Indexed.vc" width="260" height="76" /></a>